Clinical trial
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
NCT00441818 · Tanox, Industry · Unknown status
Key facts
| NCT number | NCT00441818 |
|---|---|
| Title | Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma |
| Official title | A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma |
| Lead sponsor | Tanox, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | TNX-650 |
| Enrollment | 59 |
| Start date | May 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Mar 1, 2007 |
| Last update posted | May 9, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: